CTAS Form 4: Scott Garula Receives 4,448 Restricted Shares and 17,755 Options
Rhea-AI Filing Summary
Scott Garula, VP & CFO of Cintas Corporation (CTAS), received equity awards on 08/11/2025. The filing shows 4,448 restricted common shares were granted under Cintas's Equity Compensation Plan and 17,755 stock options were awarded with an exercise price of $223.88. Following the transactions, the report shows 98,007 common shares beneficially owned (direct) and 17,755 derivative securities (options) beneficially owned (direct). The options expire on 08/11/2035 and vest in three equal tranches: one-third on the third, fourth, and fifth anniversaries of the grant date. The filing also reports 19 shares held indirectly through a 401(k) plan.
Positive
- 4,448 restricted shares granted to Scott Garula under the Cintas Equity Compensation Plan
- 17,755 stock options granted with an exercise price of $223.88 and expiration on 08/11/2035
- Vesting schedule disclosed: options vest one-third on the third, fourth, and fifth anniversaries of the grant date
- Post-transaction holdings reported: 98,007 common shares (direct) and 17,755 options (direct)
Negative
- None.
Insights
TL;DR: Routine executive compensation grants; material to insider holdings but likely neutral for valuation absent other changes.
The Form 4 documents time-based equity compensation: 4,448 restricted shares and 17,755 options at a $223.88 exercise price. Post-transaction direct common holdings are reported as 98,007 shares and 17,755 options. These awards are standard long-term incentive instruments that increase the executive's stake but will only be dilutive if exercised; the option term through 08/11/2035 provides a long exercise window.
TL;DR: Standard vesting schedule ties pay to multi-year service; disclosure is clear on vesting and expiry but does not indicate performance conditions.
The option vesting is explicitly time-based: one-third at years three, four and five, which aligns payout to continued service rather than short-term performance. The filing specifies expiration date and exercise price, and notes the restricted shares are granted under the companys equity plan. No performance-based vesting or special acceleration is disclosed in the form.